Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1569-1581

  Philis Tsimikas, Athena ^a   Charpentier, Guillaume ^b   Clauson, Per ^c   Ravn, Gabriela Martinez ^c   Roberts, Victor Lawrence ^d   Thorsteinsson, Birger ^e  

^a Whittier Institute for Diabetes   (United States)

^b CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^c NOVO NORDISK A S   (Denmark)

^d Endocrine Clinical Research   (United States)

^e HILLERØD HOSPITAL   (Denmark)

Author keywords

basal insulin; insulin detemir; insulin initiation; NPH insulin; oral antidiabetic drugs; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ATORVASTATIN; DETEMIR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN DERIVATIVE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SIMVASTATIN;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EUROPE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOCONCENTRATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33845236398     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.020     Document Type: Article

References (36)

1. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
2. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 287 (1995) 103-117
3. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
4. Available at:. International Diabetes Federation. Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Accessed June 15, 2006 (2005), IDF, Brussels, Belgium. http://www.idf.org.
5. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 Suppl 3 (2002) 518-524
6. Heinemann L. Overcoming obstacles: New management options. Eur J Endocrinol 151 Suppl 2 (2004) T23-T30
7. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 267 (2003) 3080-3086
8. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
9. Luzio S.D., Beck P., and Owens D.R. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with type 2 diabetes. Norm Metab Res 357 (2003) 434-438
10. Havelund S., Plum A., Ribel U., et al. The mechanism of protraction of insulin detemir, a long- acting, acylated analog of human insulin. Pharm Res 21 (2004) 71498-71504
11. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabet Med 20 (2003) 545-551
12. Massi Benedetti M., Humburg E., Dressler A., and Ziemen M. A one year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35 (2003) 189-196
13. Eliaschewitz F.G., Calvo C., Valbuena H., et al., HOE 901/4013 LA Study Group. Therapy in type 2 diabetes: Insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 37 (2006) 495-501
14. Vague P., Selam J.L., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
15. Standl E., Lang H., and Roberts A. The 1 2-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 6 (2004) 579-588
16. Home P., Bartley P., Russell Jones D., et al., Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
17. Russell Jones D., Simpson R., Hylleberg B., et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mel litus using a basal-bolus regimen. Clin Ther 26 (2004) 724-736
18. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
19. De Leeuw I., Vague P., Selam I.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7 (2005) 73-82
20. Pieber T.R., Draeger E., Kristensen A., and Grill V. Comparison of three multiple injection regimens for type 1 diabetes: Morning plus dinner or bedtime administration of insulin detemirvs morning plus bedtime NPH insulin. Diabet Med 22 (2005) 850-857
21. Raslova K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes [published correction appears in Diabetes Res Clin Pract. 2006;72:112]. Diabetes Res Clin Pract 66 (2004) 193-201
22. Haak T., Tiengo A., Draeger E., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in pa tients with type 2 diabetes. Diabetes Obes Metab 7 (2005) 56-64
23. Abstract. Raslova K., Karl D., and Tamer S.C. Insulin detemir is associated with less weight gain than NPH insulin, especially in the very obese, when used in basal bolus therapy for patients with type 2 diabetes. Diabetologia 48 Suppl 1 (2005) A306
24. Abstract. Klein O., Lynge J., Endahl L., et al. Insulin detemir and insulin glargine: Similar time-action profiles in subjects with type 2 diabetes. Diabetes 55 Suppl 1 (2006) A76
25. Poster. Sorensen L.P., Djurhuus C.B., Brock B., et al. No evidence for essential differences between the effects of in sulin glargine, detemir and NPH on glucose homeostasis after a single injection as assessed by 24-h euglycaemic clamp studies in healthy humans. Diabetes 55 Suppl 1 (2006) 565P
26. Plank J., Bodenlenz M., Sinner F., et al. A double-blind, randomized, closeresponse study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28 (2005) 1107-1112
27. Available at:. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site]. Accessed June 15, 2005 (1989), WMA, Ferney-Voltaire, France. http://www.wma.net
28. Available at:. European Agency for the Evaluation of Medicinal Products. Accessed June 15, 2005. International Conference on HarmonisationWorld Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int
29. Home P., and Kurtzhals P. Insulin detemir: From concept to clinical experience. Expert Opin Pharmacother 7 (2006) 325-343
30. Standl E., Maxeiner S., Raptis S., et al., HOE901/4009 Study Group. Once-daily insulin glargine adminis tration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: An assessment of treatment flexibility. Norm Metab Res 38 (2006) 172-177
31. 1c) trial. Diabetes Care 29 (2006) 1-8
32. Davies M., Storms F., Shutler S., et al., ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
33. Fritsche A., Schweitzer M.A., Haring H.U., and 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138 (2003) 952-959
34. Malone J.K., Kerr L.F., Campaigne B.N., et al., Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy [published correction appears in Clin Ther. 2005;27: 1112]. Clin Ther 26 (2004) 2034-2044
35. Raskin P., Allen E., Hollander P., et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
36. Heine R.J., Van Gaal L.F., Johns D., et al., GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial [summary for patients appears in Ann Intern Med. 2005;143: 130]. Ann Intern Med 143 (2005) 559-569